GGrantIndex
← Search

PHASE II TRIAL OF DX 8951F IN HEPATOCELLULAR CARCINOMA

$0M01FY2000RRNIH

University Of Texas Hlth Sci Ctr San Ant, San Antonio TX

Investigators

Linked publications & trials

Abstract

The study drug, an analogue of camptothecin, has demonstrated greater antitumor efficacy and water solubility than camptothecin. The present study will test its efficacy in hepatocellular carcinoma as well as document toxicity and pharmacokinetics.

View original record on NIH RePORTER →